Are high initial CEA and CA 19-9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer?

Tumor Biology

Volumn 34, Issue 4, 2013, Pages 2233-2239

  Selcukbiricik, Fatih ^a   Bilici, Ahmet ^a   Tural, Deniz ^b   Erdamar, Sibel ^b   Soyluk, Ozlem ^c   Buyukunal, Evin ^b   Demirelli, Fuat ^b   Serdengecti, Suheyla ^b  

^a Sisli Etfal Research and Educational Hospital   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c BAKIRKOY DR SADI KONUK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

CA 19 9; CEA; Colorectal cancer; K ras status; Survival

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DNA;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CANCER TISSUE; COLLOID CARCINOMA; COLON CANCER; COLORECTAL CARCINOMA; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MUTANT; ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECTUM CANCER; WILD TYPE;

EID: 84881475403     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0763-6     Document Type: Article

References (19)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013 Jan;63(1):11-30.
2. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell. 1989;57:327-34.
3. a. Biochem Biophys Res Commun. 1992;184:1048-55.
4. Hamazoe R, Maeta M, Matsui T, Shibata S, Shiota S, Kaibara N. CA72-4 compared with carcinoembryonic antigen as a tumor marker for gastric cancer. Eur J Cancer. 1992;28A:1351-4.
5. Hamazoe R, Maeta M, Matsui T, Shibata S, Shiota S, Kaibara N. CA72-4 compared with carcinoembryonic antigen as a tumor marker for gastric cancer. Eur J Cancer. 1992;28A:1351-4.
6. Formica V, Massara MC, Portarena I, Fiaschetti V, Grenga I, Del Vecchio BG, et al. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients. Cancer Biomark. 2009;5(4):167-75.
7. Van Cutsem E, Rivera F, Berry S, et al. First BEAT investigators: safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009;20:1842-7.
8. Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of K-RAS, B-RAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer. 2011;50:307-12.
9. Chao X. Zheng, Wen Hua Zhan, Ji Zong Zhao, Dong Zheng, Dong Ping Wang, et al. The prognostic value of preoperative serum levels of CEA, CA19-9 and CA72-4 in patients with colorectal cancer. World J Gastroenterol. 2001;7(3):431-4.
10. Paxton RJ, Mooser G, Pande H, Lee TD, Shively JE. Sequence analysis of carcinoembryonic antigen: identification of glycosylation sites and homology with the immunoglobulin supergene family. Proc Natl Acad Sci USA. 1987;84:920-4.
11. Lowe JB, Stoolman LM, Nair RP, Larsen RD, Berhend TL, Marks RM. ELAM-1 dependent cell adhesion to vascular endothelium determined by a transfected human fucosyltransferase cDNA. Cell. 1990;63:475-84.
12. Kornek GV, Depisch D, Rosen HR, Temsch EM, Scheithauer W. Comparative analysis of CA72-4, CA195 and carcinoembryonic antigen in patients with gastrointestinal malignancies. J Cancer Res Clin Oncol. 1992;118:318-20.
13. Ohuchi N, Takahashi K, Matoba N, Sato T, Taira Y, Sakai N, et al. Comparison of serum assays for TAG-72, CA19-9, and CEA in gastrointestinal carcinoma patients. Jpn J Clin Oncol. 1989;19:242-8.
14. Fucini C, Tommasi SM, Rosi S, Malatantis G, Cardona G, Panichi S, et al. Follow-up of colorectal cancer resected for cure. An experience with CEA, TPA, Ca19-9 analysis and second look surgery. Dis Colon Rectum. 1987;30:273-7.
15. Sato T, Nishimura G, Nonomura A, Miwa K, Miyazaki I. Serological studies on CEA, CA19-9, STn and SLX in colorectal cancer. Hepatogastroenterology. 1999;46:914-9.
16. Forones NM, Tanaka M. CEA and CA19 9 as prognostic indexes in colorectal cancer. Hepatogastroenterology. 1999;46:905-8.
17. Takada A, Ohmori K, Takahashi N, Tsuyuoka K, Yago A, Zenita K, et al. Adhesion of human cancer cells to vascular endothelium mediated by a carbohydrate antigen, sialyl Lewis A. Biochem Biophys Res Commun. 1991;179:713-9.
18. Wojciechowicz DC, Park PY, Datta RV, Paty PB. CEA is the major PHA-L-reactive glycoprotein in colon carcinoma cell lines and tumors: relationship between K-ras activation and beta1-6 branching of N-linked carbohydrate on CEA. Biochem Biophys Res Commun. 2000 24;273(1):147-53.
19. Wojciechowicz DC, Mallon RG, Picon A, Paty PB. Characterization of lectin resistant cell populations derived from human colon carcinoma: correlation of K-ras with beta1-6 branching of N-linked carbohydrate and CEA production. Biochem Biophys Res Commun. 1999 16;259(3):588-93